BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25757840)

  • 1. [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)].
    Ascaso JF; Mata P; Arbona C; Civeira F; Valdivielso P; Masana L
    Clin Investig Arterioscler; 2015; 27(2):80-96. PubMed ID: 25757840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
    Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
    Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement.
    Bruckert E
    Atheroscler Suppl; 2014 Sep; 15(2):26-32. PubMed ID: 25257074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    France M; Rees A; Datta D; Thompson G; Capps N; Ferns G; Ramaswami U; Seed M; Neely D; Cramb R; Shoulders C; Barbir M; Pottle A; Eatough R; Martin S; Bayly G; Simpson B; Halcox J; Edwards R; Main L; Payne J; Soran H;
    Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
    Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
    Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
    Cuchel M; Raal FJ; Hegele RA; Al-Rasadi K; Arca M; Averna M; Bruckert E; Freiberger T; Gaudet D; Harada-Shiba M; Hudgins LC; Kayikcioglu M; Masana L; Parhofer KG; Roeters van Lennep JE; Santos RD; Stroes ESG; Watts GF; Wiegman A; Stock JK; Tokgözoğlu LS; Catapano AL; Ray KK
    Eur Heart J; 2023 Jul; 44(25):2277-2291. PubMed ID: 37130090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
    Buonuomo PS; Macchiaiolo M; Leone G; Valente P; Mastrogiorgio G; Gnazzo M; Rana I; Gonfiantini MV; Gagliardi MG; Romano F; Bartuli A
    Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of European and US guidelines for familial hypercholesterolaemia.
    Reiner Ž
    Curr Opin Lipidol; 2015 Jun; 26(3):215-20. PubMed ID: 25943839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document].
    Mata P; Alonso R; Ruiz A; Gonzalez-Juanatey JR; Badimón L; Díaz-Díaz JL; Muñoz MT; Muñiz O; Galve E; Irigoyen L; Fuentes-Jiménez F; Dalmau J; Pérez-Jiménez F
    Semergen; 2015; 41(1):24-33. PubMed ID: 25042971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding comments.
    Catapano AL
    Atheroscler Suppl; 2014 Sep; 15(2):52. PubMed ID: 25257077
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel.
    Al-Ashwal A; Alnouri F; Sabbour H; Al-Mahfouz A; Al-Sayed N; Razzaghy-Azar M; Al-Allaf F; Al-Waili K; Banerjee Y; Genest J; Santos RD; Al-Rasadi K
    Curr Vasc Pharmacol; 2015; 13(6):759-70. PubMed ID: 26311574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
    Watts GF; Gidding S; Wierzbicki AS; Toth PP; Alonso R; Brown WV; Bruckert E; Defesche J; Lin KK; Livingston M; Mata P; Parhofer KG; Raal FJ; Santos RD; Sijbrands EJ; Simpson WG; Sullivan DR; Susekov AV; Tomlinson B; Wiegman A; Yamashita S; Kastelein JJ;
    Eur J Prev Cardiol; 2015 Jul; 22(7):849-54. PubMed ID: 24776375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
    Nordestgaard BG; Chapman MJ; Humphries SE; Ginsberg HN; Masana L; Descamps OS; Wiklund O; Hegele RA; Raal FJ; Defesche JC; Wiegman A; Santos RD; Watts GF; Parhofer KG; Hovingh GK; Kovanen PT; Boileau C; Averna M; Borén J; Bruckert E; Catapano AL; Kuivenhoven JA; Pajukanta P; Ray K; Stalenhoef AF; Stroes E; Taskinen MR; Tybjærg-Hansen A;
    Eur Heart J; 2013 Dec; 34(45):3478-90a. PubMed ID: 23956253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.